Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
Lwin M, Holroyd C, Wallis D, Davidson B, Goulston L, de Graaf H, Edwards CJ. Lwin M, et al. Among authors: de graaf h. Rheumatol Adv Pract. 2020 Oct 21;4(2):rkaa061. doi: 10.1093/rap/rkaa061. eCollection 2020. Rheumatol Adv Pract. 2020. PMID: 33210076 Free PMC article. No abstract available.
Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature.
Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, Wedderburn LR, Pilkington C, Yasin SA, Nistala K; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Binns EL, et al. Pediatr Rheumatol Online J. 2017 Oct 31;15(1):77. doi: 10.1186/s12969-017-0205-x. Pediatr Rheumatol Online J. 2017. PMID: 29089059 Free PMC article. Review.
Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features.
Yasin SA, Schutz PW, Deakin CT, Sag E, Varsani H, Simou S, Marshall LR, Tansley SL, McHugh NJ, Holton JL, Wedderburn LR, Jacques TS; UK Juvenile Dermatomyositis Research Group (UK and Ireland). Yasin SA, et al. Neuropathol Appl Neurobiol. 2019 Aug;45(5):495-512. doi: 10.1111/nan.12528. Epub 2019 Mar 11. Neuropathol Appl Neurobiol. 2019. PMID: 30378704 Free PMC article.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, Dold C, Faust SN, Finn A, Flaxman AL, Hallis B, Heath P, Jenkin D, Lazarus R, Makinson R, Minassian AM, Pollock KM, Ramasamy M, Robinson H, Snape M, Tarrant R, Voysey M, Green C, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Folegatti PM, et al. Lancet. 2020 Aug 15;396(10249):467-478. doi: 10.1016/S0140-6736(20)31604-4. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702298 Free PMC article. Clinical Trial.
Muscle Biopsy Findings in Combination With Myositis-Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis.
Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, McHugh NJ, Varsani H, Holton JL, Jacques TS, Pilkington CA, Nistala K, Wedderburn LR; UK Juvenile Dermatomyositis Research Group. Deakin CT, et al. Arthritis Rheumatol. 2016 Nov;68(11):2806-2816. doi: 10.1002/art.39753. Epub 2016 Oct 9. Arthritis Rheumatol. 2016. PMID: 27214289 Free PMC article.
Immunocompromised children and young people are at no increased risk of severe COVID-19.
Chappell H, Patel R, Driessens C, Tarr AW, Irving WL, Tighe PJ, Jackson HJ, Harvey-Cowlishaw T, Mills L, Shaunak M, Gbesemete D, Leahy A, Lucas JS, Faust SN, de Graaf H. Chappell H, et al. Among authors: de graaf h. J Infect. 2022 Jan;84(1):31-39. doi: 10.1016/j.jinf.2021.11.005. Epub 2021 Nov 14. J Infect. 2022. PMID: 34785268 Free PMC article.
140 results